These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 7749731

  • 1. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
    Kearns CM, Gash DM.
    Brain Res; 1995 Feb 20; 672(1-2):104-11. PubMed ID: 7749731
    [Abstract] [Full Text] [Related]

  • 2. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
    Tang FI, Tien LT, Zhou FC, Hoffer BJ, Wang Y.
    Exp Brain Res; 1998 Apr 20; 119(3):287-96. PubMed ID: 9551829
    [Abstract] [Full Text] [Related]

  • 3. Neuroprotective effects of GDNF against 6-OHDA in young and aged rats.
    Fox CM, Gash DM, Smoot MK, Cass WA.
    Brain Res; 2001 Mar 30; 896(1-2):56-63. PubMed ID: 11277973
    [Abstract] [Full Text] [Related]

  • 4. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
    Kirik D, Rosenblad C, Björklund A.
    Eur J Neurosci; 2000 Nov 30; 12(11):3871-82. PubMed ID: 11069582
    [Abstract] [Full Text] [Related]

  • 5. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
    Aoi M, Date I, Tomita S, Ohmoto T.
    Neurosci Res; 2000 Apr 30; 36(4):319-25. PubMed ID: 10771110
    [Abstract] [Full Text] [Related]

  • 6. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.
    Bowenkamp KE, Hoffman AF, Gerhardt GA, Henry MA, Biddle PT, Hoffer BJ, Granholm AC.
    J Comp Neurol; 1995 May 15; 355(4):479-89. PubMed ID: 7636027
    [Abstract] [Full Text] [Related]

  • 7. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C, Kirik D, Björklund A.
    Exp Neurol; 2000 Feb 15; 161(2):503-16. PubMed ID: 10686072
    [Abstract] [Full Text] [Related]

  • 8. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A.
    Eur J Neurosci; 1999 May 15; 11(5):1554-66. PubMed ID: 10215908
    [Abstract] [Full Text] [Related]

  • 9. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
    Lu X, Hagg T.
    J Comp Neurol; 1997 Nov 24; 388(3):484-94. PubMed ID: 9368855
    [Abstract] [Full Text] [Related]

  • 10. GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine.
    Cass WA, Manning MW.
    J Neurosci; 1999 Feb 15; 19(4):1416-23. PubMed ID: 9952418
    [Abstract] [Full Text] [Related]

  • 11. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.
    Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM.
    J Neurosci; 1997 Sep 15; 17(18):7111-8. PubMed ID: 9278545
    [Abstract] [Full Text] [Related]

  • 12. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.
    Wang Y, Tien LT, Lapchak PA, Hoffer BJ.
    Cell Tissue Res; 1996 Nov 15; 286(2):225-33. PubMed ID: 8854891
    [Abstract] [Full Text] [Related]

  • 13. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.
    Sullivan AM, Opacka-Juffry J, Blunt SB.
    Eur J Neurosci; 1998 Jan 15; 10(1):57-63. PubMed ID: 9753113
    [Abstract] [Full Text] [Related]

  • 14. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor.
    Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, Hoffer BJ, Mahalik TJ.
    Exp Brain Res; 1996 Sep 15; 111(1):1-7. PubMed ID: 8891630
    [Abstract] [Full Text] [Related]

  • 15. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.
    Sauer H, Rosenblad C, Björklund A.
    Proc Natl Acad Sci U S A; 1995 Sep 12; 92(19):8935-9. PubMed ID: 7568047
    [Abstract] [Full Text] [Related]

  • 16. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
    Smith AD, Kozlowski DA, Bohn MC, Zigmond MJ.
    Exp Neurol; 2005 Jun 12; 193(2):420-6. PubMed ID: 15869944
    [Abstract] [Full Text] [Related]

  • 17. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.
    Opacka-Juffry J, Ashworth S, Hume SP, Martin D, Brooks DJ, Blunt SB.
    Neuroreport; 1995 Dec 29; 7(1):348-52. PubMed ID: 8742486
    [Abstract] [Full Text] [Related]

  • 18. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, Mount DW, Wüllner U, Sherman SJ, Falk T.
    Neuroscience; 2014 Jan 31; 258():385-400. PubMed ID: 24291725
    [Abstract] [Full Text] [Related]

  • 19. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
    Ding YM, Jaumotte JD, Signore AP, Zigmond MJ.
    J Neurochem; 2004 May 31; 89(3):776-87. PubMed ID: 15086533
    [Abstract] [Full Text] [Related]

  • 20. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM, Ortiz R, Dye S, Campbell RB, Amiji MM, Waszczak BL.
    Neuroscience; 2014 Aug 22; 274():11-23. PubMed ID: 24845869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.